118 related articles for article (PubMed ID: 33689058)
1. Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer.
Moossdorff M; Vane MLG; van Nijnatten TJA; van Maaren MC; Goorts B; Heuts EM; Strobbe LJA; Smidt ML
Breast Cancer Res Treat; 2021 Apr; 186(3):863-870. PubMed ID: 33689058
[TBL] [Abstract][Full Text] [Related]
2. Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer.
Kitano S; Tsunashima R; Kato C; Watanabe A; Sota Y; Matsumoto S; Morita M; Sakaguchi K; Naoi Y
Breast Cancer; 2024 Jun; ():. PubMed ID: 38862868
[TBL] [Abstract][Full Text] [Related]
3. Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands.
Walstra CJEF; Schipper RJ; van Riet YE; van der Toorn PG; Smidt ML; Sangen MJCV; Voogd AC; Nieuwenhuijzen GAP
Breast Cancer Res Treat; 2021 Jun; 187(2):499-514. PubMed ID: 33713244
[TBL] [Abstract][Full Text] [Related]
4. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis.
Tamirisa N; Lin H; Shen Y; Shaitelman SF; Karuturi MS; Giordano SH; Babiera GV; Bedrosian I
Cancer; 2021 Jul; 127(13):2196-2203. PubMed ID: 33735487
[TBL] [Abstract][Full Text] [Related]
5. Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial.
Faltinová M; Vehmanen L; Lyytinen H; Haanpää M; Hämäläinen E; Tiitinen A; Blomqvist C; Mattson J
Breast Cancer Res Treat; 2021 Jun; 187(3):769-775. PubMed ID: 33710439
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases.
Hetterich M; Gerken M; Ortmann O; Inwald EC; Klinkhammer-Schalke M; Eggemann H; Ignatov A
Breast Cancer Res Treat; 2021 Jun; 187(3):715-727. PubMed ID: 33721148
[TBL] [Abstract][Full Text] [Related]
7. Next-Generation Endocrine Therapies for Breast Cancer.
McDonnell DP; Wardell SE; Chang CY; Norris JD
J Clin Oncol; 2021 Apr; 39(12):1383-1388. PubMed ID: 33705209
[No Abstract] [Full Text] [Related]
8. Characterization of estrogen receptor-low-positive breast cancer.
Fei F; Siegal GP; Wei S
Breast Cancer Res Treat; 2021 Jul; 188(1):225-235. PubMed ID: 33694051
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer.
Loibl S; Poortmans P; Morrow M; Denkert C; Curigliano G
Lancet; 2021 May; 397(10286):1750-1769. PubMed ID: 33812473
[TBL] [Abstract][Full Text] [Related]
10. Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
Metcalfe KA; Eisen A; Poll A; Candib A; McCready D; Cil T; Wright F; Demsky R; Mancuso T; Sun P; Narod SA
Ann Surg Oncol; 2021 Sep; 28(9):4967-4973. PubMed ID: 33761021
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
Perez J; Garrigós L; Gion M; Jänne PA; Shitara K; Siena S; Cortés J
Expert Opin Biol Ther; 2021 Jul; 21(7):811-824. PubMed ID: 33759669
[TBL] [Abstract][Full Text] [Related]
12. Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
Ibragimova KIE; Geurts SME; Croes S; Erdkamp F; Heijns JB; Tol J; Vriens BEPJ; Aaldering KNA; Dercksen MW; Pepels MJAE; Peters NAJB; van de Winkel L; Tilli DJP; Vriens IJH; de Boer M; Tjan-Heijnen VCG
Breast Cancer Res Treat; 2021 Jul; 188(2):571-581. PubMed ID: 33743103
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study.
Lloyd KE; Hall LH; Ziegler L; Smith SG;
Breast Cancer Res Treat; 2021 Aug; 188(3):703-712. PubMed ID: 33733302
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer rate after oophorectomy: A Prospective Danish Cohort Study.
Koch T; Jørgensen JT; Christensen J; Dehlendorff C; Priskorn L; Simonsen MK; Duun-Henriksen AK; Andersen ZJ; Juul A; Bräuner EV; Hickey M
Int J Cancer; 2021 Aug; 149(3):585-593. PubMed ID: 33729548
[TBL] [Abstract][Full Text] [Related]
15. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
[TBL] [Abstract][Full Text] [Related]
16. Identifying unmet needs and limitations in physical health in survivors of Head and Neck Cancer.
van Hinte G; Leijendekkers RA; Merkx MAW; Takes RP; Nijhuis-van der Sanden MWG; Speksnijder CM
Eur J Cancer Care (Engl); 2021 Sep; 30(5):e13434. PubMed ID: 33709466
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.
Zeppellini A; Galimberti S; Leone BE; Pacifico C; Riva F; Cicchiello F; Capici S; Maggioni C; Sala L; Cazzaniga ME
BMC Cancer; 2021 Mar; 21(1):260. PubMed ID: 33691674
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer preoperative
Vinh-Hung V; Everaert H; Gorobets O; Van Parijs H; Verfaillie G; Vanhoeij M; Storme G; Fontaine C; Lamote J; Perrin J; Farid K; Nguyen NP; Verschraegen C; De Ridder M
Breast Cancer; 2021 Jul; 28(4):956-968. PubMed ID: 33689151
[TBL] [Abstract][Full Text] [Related]
19. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer mortality after eight years of an improved screening program using digital breast tomosynthesis.
Castellano CR; Aguilar Angulo PM; Hernández LC; González-Carrato PS; González RG; Alvarez J; Chacón JI; Ruiz J; Fuentes Guillén MÁ; Gutiérrez Ávila G
J Med Screen; 2021 Dec; 28(4):456-463. PubMed ID: 33775181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
